The global market for Treatments for Alpha-1 was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Treatments for Alpha-1, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Treatments for Alpha-1 by region & country, by Type, and by Application.

The Treatments for Alpha-1 market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Treatments for Alpha-1.

Market Segmentation

Scope of Treatments for Alpha-1 - Market Report

Report Metric	Details
Report Name	Treatments for Alpha-1 - Market
CAGR	5%
Segment by Type:	Augmentation Therapy Cystic Fibrosis(CF) Non-CF Bronchiectasis(NCFB) Diabetes Other
Segment by Application	Hospitals Specialty Clinics Pharmacies
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical Industries, Takeda, Baxter, Grifols, CSL Behring, Kamada Ltd, Chiesi Pharmaceuticals, Kedrion Group, Vertex Pharmaceuticals, ProMetic Life Sciences
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Treatments for Alpha-1 manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Treatments for Alpha-1 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Treatments for Alpha-1 in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Treatments for Alpha-1 - Market report?

Ans: The main players in the Treatments for Alpha-1 - Market are Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical Industries, Takeda, Baxter, Grifols, CSL Behring, Kamada Ltd, Chiesi Pharmaceuticals, Kedrion Group, Vertex Pharmaceuticals, ProMetic Life Sciences

What are the Application segmentation covered in the Treatments for Alpha-1 - Market report?

Ans: The Applications covered in the Treatments for Alpha-1 - Market report are Hospitals, Specialty Clinics, Pharmacies

What are the Type segmentation covered in the Treatments for Alpha-1 - Market report?

Ans: The Types covered in the Treatments for Alpha-1 - Market report are Augmentation Therapy, Cystic Fibrosis(CF), Non-CF Bronchiectasis(NCFB), Diabetes, Other

1 Market Overview

1.1 Treatments for Alpha-1 Product Introduction

1.2 Global Treatments for Alpha-1 Market Size Forecast

1.3 Treatments for Alpha-1 Market Trends & Drivers

1.3.1 Treatments for Alpha-1 Industry Trends

1.3.2 Treatments for Alpha-1 Market Drivers & Opportunity

1.3.3 Treatments for Alpha-1 Market Challenges

1.3.4 Treatments for Alpha-1 Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Treatments for Alpha-1 Players Revenue Ranking (2023)

2.2 Global Treatments for Alpha-1 Revenue by Company (2019-2024)

2.3 Key Companies Treatments for Alpha-1 Manufacturing Base Distribution and Headquarters

2.4 Key Companies Treatments for Alpha-1 Product Offered

2.5 Key Companies Time to Begin Mass Production of Treatments for Alpha-1

2.6 Treatments for Alpha-1 Market Competitive Analysis

2.6.1 Treatments for Alpha-1 Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Treatments for Alpha-1 Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Treatments for Alpha-1 as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Augmentation Therapy

3.1.2 Cystic Fibrosis(CF)

3.1.3 Non-CF Bronchiectasis(NCFB)

3.1.4 Diabetes

3.1.5 Other

3.2 Global Treatments for Alpha-1 Sales Value by Type

3.2.1 Global Treatments for Alpha-1 Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Treatments for Alpha-1 Sales Value, by Type (2019-2030)

3.2.3 Global Treatments for Alpha-1 Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospitals

4.1.2 Specialty Clinics

4.1.3 Pharmacies

4.2 Global Treatments for Alpha-1 Sales Value by Application

4.2.1 Global Treatments for Alpha-1 Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Treatments for Alpha-1 Sales Value, by Application (2019-2030)

4.2.3 Global Treatments for Alpha-1 Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Treatments for Alpha-1 Sales Value by Region

5.1.1 Global Treatments for Alpha-1 Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Treatments for Alpha-1 Sales Value by Region (2019-2024)

5.1.3 Global Treatments for Alpha-1 Sales Value by Region (2025-2030)

5.1.4 Global Treatments for Alpha-1 Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Treatments for Alpha-1 Sales Value, 2019-2030

5.2.2 North America Treatments for Alpha-1 Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Treatments for Alpha-1 Sales Value, 2019-2030

5.3.2 Europe Treatments for Alpha-1 Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Treatments for Alpha-1 Sales Value, 2019-2030

5.4.2 Asia Pacific Treatments for Alpha-1 Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Treatments for Alpha-1 Sales Value, 2019-2030

5.5.2 South America Treatments for Alpha-1 Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Treatments for Alpha-1 Sales Value, 2019-2030

5.6.2 Middle East & Africa Treatments for Alpha-1 Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Treatments for Alpha-1 Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Treatments for Alpha-1 Sales Value

6.3 United States

6.3.1 United States Treatments for Alpha-1 Sales Value, 2019-2030

6.3.2 United States Treatments for Alpha-1 Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Treatments for Alpha-1 Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Treatments for Alpha-1 Sales Value, 2019-2030

6.4.2 Europe Treatments for Alpha-1 Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Treatments for Alpha-1 Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Treatments for Alpha-1 Sales Value, 2019-2030

6.5.2 China Treatments for Alpha-1 Sales Value by Type (%), 2023 VS 2030

6.5.3 China Treatments for Alpha-1 Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Treatments for Alpha-1 Sales Value, 2019-2030

6.6.2 Japan Treatments for Alpha-1 Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Treatments for Alpha-1 Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Treatments for Alpha-1 Sales Value, 2019-2030

6.7.2 South Korea Treatments for Alpha-1 Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Treatments for Alpha-1 Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Treatments for Alpha-1 Sales Value, 2019-2030

6.8.2 Southeast Asia Treatments for Alpha-1 Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Treatments for Alpha-1 Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Treatments for Alpha-1 Sales Value, 2019-2030

6.9.2 India Treatments for Alpha-1 Sales Value by Type (%), 2023 VS 2030

6.9.3 India Treatments for Alpha-1 Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Pfizer

7.1.1 Pfizer Profile

7.1.2 Pfizer Main Business

7.1.3 Pfizer Treatments for Alpha-1 Products, Services and Solutions

7.1.4 Pfizer Treatments for Alpha-1 Revenue (US$ Million) & (2019-2024)

7.1.5 Pfizer Recent Developments

7.2 GlaxoSmithKline

7.2.1 GlaxoSmithKline Profile

7.2.2 GlaxoSmithKline Main Business

7.2.3 GlaxoSmithKline Treatments for Alpha-1 Products, Services and Solutions

7.2.4 GlaxoSmithKline Treatments for Alpha-1 Revenue (US$ Million) & (2019-2024)

7.2.5 GlaxoSmithKline Recent Developments

7.3 AstraZeneca

7.3.1 AstraZeneca Profile

7.3.2 AstraZeneca Main Business

7.3.3 AstraZeneca Treatments for Alpha-1 Products, Services and Solutions

7.3.4 AstraZeneca Treatments for Alpha-1 Revenue (US$ Million) & (2019-2024)

7.3.5 Boehringer Ingelheim Recent Developments

7.4 Boehringer Ingelheim

7.4.1 Boehringer Ingelheim Profile

7.4.2 Boehringer Ingelheim Main Business

7.4.3 Boehringer Ingelheim Treatments for Alpha-1 Products, Services and Solutions

7.4.4 Boehringer Ingelheim Treatments for Alpha-1 Revenue (US$ Million) & (2019-2024)

7.4.5 Boehringer Ingelheim Recent Developments

7.5 Teva Pharmaceutical Industries

7.5.1 Teva Pharmaceutical Industries Profile

7.5.2 Teva Pharmaceutical Industries Main Business

7.5.3 Teva Pharmaceutical Industries Treatments for Alpha-1 Products, Services and Solutions

7.5.4 Teva Pharmaceutical Industries Treatments for Alpha-1 Revenue (US$ Million) & (2019-2024)

7.5.5 Teva Pharmaceutical Industries Recent Developments

7.6 Takeda

7.6.1 Takeda Profile

7.6.2 Takeda Main Business

7.6.3 Takeda Treatments for Alpha-1 Products, Services and Solutions

7.6.4 Takeda Treatments for Alpha-1 Revenue (US$ Million) & (2019-2024)

7.6.5 Takeda Recent Developments

7.7 Baxter

7.7.1 Baxter Profile

7.7.2 Baxter Main Business

7.7.3 Baxter Treatments for Alpha-1 Products, Services and Solutions

7.7.4 Baxter Treatments for Alpha-1 Revenue (US$ Million) & (2019-2024)

7.7.5 Baxter Recent Developments

7.8 Grifols

7.8.1 Grifols Profile

7.8.2 Grifols Main Business

7.8.3 Grifols Treatments for Alpha-1 Products, Services and Solutions

7.8.4 Grifols Treatments for Alpha-1 Revenue (US$ Million) & (2019-2024)

7.8.5 Grifols Recent Developments

7.9 CSL Behring

7.9.1 CSL Behring Profile

7.9.2 CSL Behring Main Business

7.9.3 CSL Behring Treatments for Alpha-1 Products, Services and Solutions

7.9.4 CSL Behring Treatments for Alpha-1 Revenue (US$ Million) & (2019-2024)

7.9.5 CSL Behring Recent Developments

7.10 Kamada Ltd

7.10.1 Kamada Ltd Profile

7.10.2 Kamada Ltd Main Business

7.10.3 Kamada Ltd Treatments for Alpha-1 Products, Services and Solutions

7.10.4 Kamada Ltd Treatments for Alpha-1 Revenue (US$ Million) & (2019-2024)

7.10.5 Kamada Ltd Recent Developments

7.11 Chiesi Pharmaceuticals

7.11.1 Chiesi Pharmaceuticals Profile

7.11.2 Chiesi Pharmaceuticals Main Business

7.11.3 Chiesi Pharmaceuticals Treatments for Alpha-1 Products, Services and Solutions

7.11.4 Chiesi Pharmaceuticals Treatments for Alpha-1 Revenue (US$ Million) & (2019-2024)

7.11.5 Chiesi Pharmaceuticals Recent Developments

7.12 Kedrion Group

7.12.1 Kedrion Group Profile

7.12.2 Kedrion Group Main Business

7.12.3 Kedrion Group Treatments for Alpha-1 Products, Services and Solutions

7.12.4 Kedrion Group Treatments for Alpha-1 Revenue (US$ Million) & (2019-2024)

7.12.5 Kedrion Group Recent Developments

7.13 Vertex Pharmaceuticals

7.13.1 Vertex Pharmaceuticals Profile

7.13.2 Vertex Pharmaceuticals Main Business

7.13.3 Vertex Pharmaceuticals Treatments for Alpha-1 Products, Services and Solutions

7.13.4 Vertex Pharmaceuticals Treatments for Alpha-1 Revenue (US$ Million) & (2019-2024)

7.13.5 Vertex Pharmaceuticals Recent Developments

7.14 ProMetic Life Sciences

7.14.1 ProMetic Life Sciences Profile

7.14.2 ProMetic Life Sciences Main Business

7.14.3 ProMetic Life Sciences Treatments for Alpha-1 Products, Services and Solutions

7.14.4 ProMetic Life Sciences Treatments for Alpha-1 Revenue (US$ Million) & (2019-2024)

7.14.5 ProMetic Life Sciences Recent Developments

8 Industry Chain Analysis

8.1 Treatments for Alpha-1 Industrial Chain

8.2 Treatments for Alpha-1 Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Treatments for Alpha-1 Sales Model

8.5.2 Sales Channel

8.5.3 Treatments for Alpha-1 Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Boehringer Ingelheim

Teva Pharmaceutical Industries

Chiesi Pharmaceuticals

Kedrion Group

Vertex Pharmaceuticals

ProMetic Life Sciences

Astrazeneca plc

GlaxoSmithKline PLC

Pfizer Inc

List of Tables

Table 1. Treatments for Alpha-1 Market Trends

Table 2. Treatments for Alpha-1 Market Drivers & Opportunity

Table 3. Treatments for Alpha-1 Market Challenges

Table 4. Treatments for Alpha-1 Market Restraints

Table 5. Global Treatments for Alpha-1 Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Treatments for Alpha-1 Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Treatments for Alpha-1 Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Treatments for Alpha-1 Product Type

Table 9. Key Companies Time to Begin Mass Production of Treatments for Alpha-1

Table 10. Global Treatments for Alpha-1 Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Treatments for Alpha-1 as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Treatments for Alpha-1 Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Treatments for Alpha-1 Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Treatments for Alpha-1 Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Treatments for Alpha-1 Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Treatments for Alpha-1 Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Treatments for Alpha-1 Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Treatments for Alpha-1 Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Treatments for Alpha-1 Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Treatments for Alpha-1 Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Treatments for Alpha-1 Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Treatments for Alpha-1 Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Treatments for Alpha-1 Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Treatments for Alpha-1 Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Treatments for Alpha-1 Sales Value by Region (2019-2024) & (%)

Table 27. Global Treatments for Alpha-1 Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Treatments for Alpha-1 Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Treatments for Alpha-1 Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Treatments for Alpha-1 Sales Value, (2025-2030) & (US$ Million)

Table 31. Pfizer Basic Information List

Table 32. Pfizer Description and Business Overview

Table 33. Pfizer Treatments for Alpha-1 Products, Services and Solutions

Table 34. Revenue (US$ Million) in Treatments for Alpha-1 Business of Pfizer (2019-2024)

Table 35. Pfizer Recent Developments

Table 36. GlaxoSmithKline Basic Information List

Table 37. GlaxoSmithKline Description and Business Overview

Table 38. GlaxoSmithKline Treatments for Alpha-1 Products, Services and Solutions

Table 39. Revenue (US$ Million) in Treatments for Alpha-1 Business of GlaxoSmithKline (2019-2024)

Table 40. GlaxoSmithKline Recent Developments

Table 41. AstraZeneca Basic Information List

Table 42. AstraZeneca Description and Business Overview

Table 43. AstraZeneca Treatments for Alpha-1 Products, Services and Solutions

Table 44. Revenue (US$ Million) in Treatments for Alpha-1 Business of AstraZeneca (2019-2024)

Table 45. AstraZeneca Recent Developments

Table 46. Boehringer Ingelheim Basic Information List

Table 47. Boehringer Ingelheim Description and Business Overview

Table 48. Boehringer Ingelheim Treatments for Alpha-1 Products, Services and Solutions

Table 49. Revenue (US$ Million) in Treatments for Alpha-1 Business of Boehringer Ingelheim (2019-2024)

Table 50. Boehringer Ingelheim Recent Developments

Table 51. Teva Pharmaceutical Industries Basic Information List

Table 52. Teva Pharmaceutical Industries Description and Business Overview

Table 53. Teva Pharmaceutical Industries Treatments for Alpha-1 Products, Services and Solutions

Table 54. Revenue (US$ Million) in Treatments for Alpha-1 Business of Teva Pharmaceutical Industries (2019-2024)

Table 55. Teva Pharmaceutical Industries Recent Developments

Table 56. Takeda Basic Information List

Table 57. Takeda Description and Business Overview

Table 58. Takeda Treatments for Alpha-1 Products, Services and Solutions

Table 59. Revenue (US$ Million) in Treatments for Alpha-1 Business of Takeda (2019-2024)

Table 60. Takeda Recent Developments

Table 61. Baxter Basic Information List

Table 62. Baxter Description and Business Overview

Table 63. Baxter Treatments for Alpha-1 Products, Services and Solutions

Table 64. Revenue (US$ Million) in Treatments for Alpha-1 Business of Baxter (2019-2024)

Table 65. Baxter Recent Developments

Table 66. Grifols Basic Information List

Table 67. Grifols Description and Business Overview

Table 68. Grifols Treatments for Alpha-1 Products, Services and Solutions

Table 69. Revenue (US$ Million) in Treatments for Alpha-1 Business of Grifols (2019-2024)

Table 70. Grifols Recent Developments

Table 71. CSL Behring Basic Information List

Table 72. CSL Behring Description and Business Overview

Table 73. CSL Behring Treatments for Alpha-1 Products, Services and Solutions

Table 74. Revenue (US$ Million) in Treatments for Alpha-1 Business of CSL Behring (2019-2024)

Table 75. CSL Behring Recent Developments

Table 76. Kamada Ltd Basic Information List

Table 77. Kamada Ltd Description and Business Overview

Table 78. Kamada Ltd Treatments for Alpha-1 Products, Services and Solutions

Table 79. Revenue (US$ Million) in Treatments for Alpha-1 Business of Kamada Ltd (2019-2024)

Table 80. Kamada Ltd Recent Developments

Table 81. Chiesi Pharmaceuticals Basic Information List

Table 82. Chiesi Pharmaceuticals Description and Business Overview

Table 83. Chiesi Pharmaceuticals Treatments for Alpha-1 Products, Services and Solutions

Table 84. Revenue (US$ Million) in Treatments for Alpha-1 Business of Chiesi Pharmaceuticals (2019-2024)

Table 85. Chiesi Pharmaceuticals Recent Developments

Table 86. Kedrion Group Basic Information List

Table 87. Kedrion Group Description and Business Overview

Table 88. Kedrion Group Treatments for Alpha-1 Products, Services and Solutions

Table 89. Revenue (US$ Million) in Treatments for Alpha-1 Business of Kedrion Group (2019-2024)

Table 90. Kedrion Group Recent Developments

Table 91. Vertex Pharmaceuticals Basic Information List

Table 92. Vertex Pharmaceuticals Description and Business Overview

Table 93. Vertex Pharmaceuticals Treatments for Alpha-1 Products, Services and Solutions

Table 94. Revenue (US$ Million) in Treatments for Alpha-1 Business of Vertex Pharmaceuticals (2019-2024)

Table 95. Vertex Pharmaceuticals Recent Developments

Table 96. ProMetic Life Sciences Basic Information List

Table 97. ProMetic Life Sciences Description and Business Overview

Table 98. ProMetic Life Sciences Treatments for Alpha-1 Products, Services and Solutions

Table 99. Revenue (US$ Million) in Treatments for Alpha-1 Business of ProMetic Life Sciences (2019-2024)

Table 100. ProMetic Life Sciences Recent Developments

Table 101. Key Raw Materials Lists

Table 102. Raw Materials Key Suppliers Lists

Table 103. Treatments for Alpha-1 Downstream Customers

Table 104. Treatments for Alpha-1 Distributors List

Table 105. Research Programs/Design for This Report

Table 106. Key Data Information from Secondary Sources

Table 107. Key Data Information from Primary Sources

Table 108. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Treatments for Alpha-1 Product Picture

Figure 2. Global Treatments for Alpha-1 Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Treatments for Alpha-1 Sales Value (2019-2030) & (US$ Million)

Figure 4. Treatments for Alpha-1 Report Years Considered

Figure 5. Global Treatments for Alpha-1 Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Treatments for Alpha-1 Revenue in 2023

Figure 7. Treatments for Alpha-1 Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Augmentation Therapy Picture

Figure 9. Cystic Fibrosis(CF) Picture

Figure 10. Non-CF Bronchiectasis(NCFB) Picture

Figure 11. Diabetes Picture

Figure 12. Other Picture

Figure 13. Global Treatments for Alpha-1 Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 14. Global Treatments for Alpha-1 Sales Value Market Share by Type, 2023 & 2030

Figure 15. Product Picture of Hospitals

Figure 16. Product Picture of Specialty Clinics

Figure 17. Product Picture of Pharmacies

Figure 18. Global Treatments for Alpha-1 Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 19. Global Treatments for Alpha-1 Sales Value Market Share by Application, 2023 & 2030

Figure 20. North America Treatments for Alpha-1 Sales Value (2019-2030) & (US$ Million)

Figure 21. North America Treatments for Alpha-1 Sales Value by Country (%), 2023 VS 2030

Figure 22. Europe Treatments for Alpha-1 Sales Value (2019-2030) & (US$ Million)

Figure 23. Europe Treatments for Alpha-1 Sales Value by Country (%), 2023 VS 2030

Figure 24. Asia Pacific Treatments for Alpha-1 Sales Value (2019-2030) & (US$ Million)

Figure 25. Asia Pacific Treatments for Alpha-1 Sales Value by Country (%), 2023 VS 2030

Figure 26. South America Treatments for Alpha-1 Sales Value (2019-2030) & (US$ Million)

Figure 27. South America Treatments for Alpha-1 Sales Value by Country (%), 2023 VS 2030

Figure 28. Middle East & Africa Treatments for Alpha-1 Sales Value (2019-2030) & (US$ Million)

Figure 29. Middle East & Africa Treatments for Alpha-1 Sales Value by Country (%), 2023 VS 2030

Figure 30. Key Countries/Regions Treatments for Alpha-1 Sales Value (%), (2019-2030)

Figure 31. United States Treatments for Alpha-1 Sales Value, (2019-2030) & (US$ Million)

Figure 32. United States Treatments for Alpha-1 Sales Value by Type (%), 2023 VS 2030

Figure 33. United States Treatments for Alpha-1 Sales Value by Application (%), 2023 VS 2030

Figure 34. Europe Treatments for Alpha-1 Sales Value, (2019-2030) & (US$ Million)

Figure 35. Europe Treatments for Alpha-1 Sales Value by Type (%), 2023 VS 2030

Figure 36. Europe Treatments for Alpha-1 Sales Value by Application (%), 2023 VS 2030

Figure 37. China Treatments for Alpha-1 Sales Value, (2019-2030) & (US$ Million)

Figure 38. China Treatments for Alpha-1 Sales Value by Type (%), 2023 VS 2030

Figure 39. China Treatments for Alpha-1 Sales Value by Application (%), 2023 VS 2030

Figure 40. Japan Treatments for Alpha-1 Sales Value, (2019-2030) & (US$ Million)

Figure 41. Japan Treatments for Alpha-1 Sales Value by Type (%), 2023 VS 2030

Figure 42. Japan Treatments for Alpha-1 Sales Value by Application (%), 2023 VS 2030

Figure 43. South Korea Treatments for Alpha-1 Sales Value, (2019-2030) & (US$ Million)

Figure 44. South Korea Treatments for Alpha-1 Sales Value by Type (%), 2023 VS 2030

Figure 45. South Korea Treatments for Alpha-1 Sales Value by Application (%), 2023 VS 2030

Figure 46. Southeast Asia Treatments for Alpha-1 Sales Value, (2019-2030) & (US$ Million)

Figure 47. Southeast Asia Treatments for Alpha-1 Sales Value by Type (%), 2023 VS 2030

Figure 48. Southeast Asia Treatments for Alpha-1 Sales Value by Application (%), 2023 VS 2030

Figure 49. India Treatments for Alpha-1 Sales Value, (2019-2030) & (US$ Million)

Figure 50. India Treatments for Alpha-1 Sales Value by Type (%), 2023 VS 2030

Figure 51. India Treatments for Alpha-1 Sales Value by Application (%), 2023 VS 2030

Figure 52. Treatments for Alpha-1 Industrial Chain

Figure 53. Treatments for Alpha-1 Manufacturing Cost Structure

Figure 54. Channels of Distribution (Direct Sales, and Distribution)

Figure 55. Bottom-up and Top-down Approaches for This Report

Figure 56. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-17Q10023

Fri Dec 27 00:00:00 UTC 2024

Add to Cart

Global Pre-Clinical Chemistry Testing Device for Laboratory Animal Models Market Insights, Forecast to 2030

120 Pages

Type: Report

Code: QYRE-Auto-8U10163

Fri Dec 27 00:00:00 UTC 2024

Add to Cart

Global Fast-disintegrating Tablets Market Insights, Forecast to 2030

120 Pages

Type: Report

Code: QYRE-Auto-11I9951

Fri Dec 27 00:00:00 UTC 2024

Add to Cart

Global Immuno Oncology Assays Kit Market Insights, Forecast to 2030

120 Pages

Type: Report

Code: QYRE-Auto-34H832

Fri Dec 27 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Treatments for Alpha-1 - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Published Date: September 2024

Report Code: QYRE-Auto-29X12758

Treatments for Alpha-1 - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

FEATURED COMPANIES

Treatments for Alpha-1 - Market Size

Treatments for Alpha-1 - Market

Report Scope

Scope of Treatments for Alpha-1 - Market Report

Chapter Outline

FAQ for this report

Who are the main players in the Treatments for Alpha-1 - Market report?

What are the Application segmentation covered in the Treatments for Alpha-1 - Market report?

What are the Type segmentation covered in the Treatments for Alpha-1 - Market report?

FEATURED COMPANIES

RELATED REPORTS